2014's Most Shocking Takeover

Despite investigations into the composition of its key drug, Acthar gel, as well as into its marketing practices, Questcor Pharmaceuticals (NASDAQ: QCOR.DL  ) has announced that it is being bought by Mallinckrodt (NYSE: MNK  ) for $5.6 billion. Short-sellers have been attacking Questcor relentlessly recently, alleging that the stock could, in fact, be worth nothing if Acthar's composition is found not to be what the company claims.

In this video, Motley Fool health-care analyst David Williamson looks at the purchase, which was at a 27% premium to the stock's price, and discusses the pros and cons for Mallinckrodt. He also tells Questcor bulls everywhere that this signals the end of the battle for Questcor investors, and that they've officially won the fight on this stock over the bears.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology  behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2906262, ~/Articles/ArticleHandler.aspx, 9/2/2015 10:56:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,162.91 104.56 0.65%
S&P 500 1,923.97 10.12 0.53%
NASD 4,666.74 30.64 0.66%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 10:40 AM
MNK $84.29 Up +0.23 +0.27%
Mallinckrodt plc CAPS Rating: ***
QCOR.DL $0.00 Down +0.00 +0.00%
Questcor Pharmaceu… CAPS Rating: **